Core Viewpoint - The event "投海Demo Day·脑机接口闭门沙龙" successfully facilitated deep exchanges among various stakeholders in the brain-computer interface (BCI) field, aiming to drive the transition of BCI technology from laboratory to clinical application and industrialization [1] Group 1: Event Overview - The event was hosted by the Zhongguancun Science City Management Committee and supported by various institutions, including the Haidian District Disabled Persons' Federation and several investment firms [1] - Over 60 ecological funds and industry enterprises participated, creating a multi-faceted platform for collaboration among government, industry, academia, research, and medical applications [1] Group 2: Project Presentations - Six innovative projects showcased diverse technological pathways in the BCI field, including non-invasive, invasive, and minimally invasive techniques [3] - EMOTIV, a leading non-invasive BCI company from Silicon Valley, plans to enter the Chinese market in summer 2025, focusing on consumer interaction, commercial applications, and medical diagnostic support [3] - Other companies presented included: - 柚果科技, offering a full-chain solution from auxiliary examination to precise treatment using non-invasive BCI and AI technologies [4] - 明视脑机, specializing in neurophysiological devices for brain science and rehabilitation [4] - 灵犀医学, focusing on medical BCI and AI for brain disease analysis [4] - 中科意象, providing minimally invasive implanted BCI systems for various neurological disorders [4] - 柔灵科技, with products like brain-sleep monitoring patches and neuromuscular hand rings [4] Group 3: Roundtable Discussions - Two roundtable forums discussed "Technological Breakthroughs and Clinical Transformation" and "Industry Ecosystem and Policy Support," featuring insights from experts across clinical, academic, capital, and corporate sectors [7] - The first forum highlighted challenges in clinical transformation, emphasizing the need for better collaboration between medical and engineering fields, as well as the establishment of rigorous clinical trial quality control [8] - The second forum focused on creating a supportive environment for long-term industry development, advocating for the construction of clinical demand databases and ethical frameworks to build public trust [10] Group 4: Outcomes and Future Prospects - The event successfully established an efficient platform for connecting technology, capital, and application scenarios, promoting resource aggregation and industry collaboration in the BCI field [13] - Preliminary cooperation intentions were established between over twenty investment institutions and presenting companies, indicating a positive outlook for the BCI industry in Haidian [13]